Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 23;41(5):122.
doi: 10.1007/s12032-024-02368-8.

Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy

Abdur Rauf  1 , Payal B Joshi  2 , Ahmed Olatunde  3 , Nabia Hafeez  4 , Zubair Ahmad  1 , Hassan A Hemeg  5 , Abdullah S M Aljohani  6 , Waleed Al Abdulmonem  7 , Muthu Thiruvengadam  8 , Dhivya Viswanathan  9 , Govindasamy Rajakumar  10 , Rekha Thiruvengadam  11
Affiliations
Review

Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy

Abdur Rauf et al. Med Oncol. .

Abstract

Drug repositioning or repurposing has gained worldwide attention as a plausible way to search for novel molecules for the treatment of particular diseases or disorders. Drug repurposing essentially refers to uncovering approved or failed compounds for use in various diseases. Cancer is a deadly disease and leading cause of mortality. The search for approved non-oncologic drugs for cancer treatment involved in silico modeling, databases, and literature searches. In this review, we provide a concise account of the existing non-oncologic drug molecules and their therapeutic potential in chemotherapy. The mechanisms and modes of action of the repurposed drugs using computational techniques are also highlighted. Furthermore, we discuss potential targets, critical pathways, and highlight in detail the different challenges pertaining to drug repositioning for cancer immunotherapy.

Keywords: Cancer; Computational tools; Drug repositioning; Drug repurposing; Immunotherapy; Non-oncologic drugs.

PubMed Disclaimer

References

    1. Olatunde A, Nigam M, Singh RK, Panwar AS, Lasisi A, Alhumaydhi FA, Jyoti kumar V, et al. Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs. Cancer Cell Int. 2021;21(1):499. https://doi.org/10.1186/s12935-021-02202-5 . - DOI - PubMed - PMC
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 . - DOI - PubMed
    1. Fu L, Jin W, Zhang J, Zhu L, Lu J, Zhen Y, et al. Repurposing non-oncology small-molecule drugs to improve cancer therapy: current situation and future directions. Acta Pharm Sin B. 2022;12(2):532–57. https://doi.org/10.1016/j.apsb.2021.09.006 . - DOI - PubMed
    1. Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177(11):1569–75. https://doi.org/10.1001/jamainternmed.2017.3601 . - DOI - PubMed - PMC
    1. Kaushik I, Ramachandran S, Prasad S, Srivastava SK. Drug rechanneling: a novel paradigm for cancer treatment. Semin Cancer Biol. 2021;68:279–90. https://doi.org/10.1016/j.semcancer.2020.03.011 . - DOI - PubMed

Substances

LinkOut - more resources